Trial · NCT01470859
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Longitudinal Change of Brain Network Activity | Levodopa | Change from baseline (V5-V1) | 0.41 | Standard Deviation 0.70 | Z-score in PDRP |
| Longitudinal Change of Brain Network Activity | Pramipexole | Change from baseline (V5-V1) | 0.61 | Standard Deviation 0.68 | Z-score in PDRP |
| Longitudinal Change of Brain Network Activity | Levodopa | Z score at baseline (V1) | 2.21 | Standard Deviation 1.54 | Z-score in PDRP |
| Longitudinal Change of Brain Network Activity | Pramipexole | Z score at baseline (V1) | 3.61 | Standard Deviation 1.77 | Z-score in PDRP |
| Longitudinal Change of Brain Network Activity | Levodopa | Z score at 1 year (V5) | 2.29 | Standard Deviation 1.24 | Z-score in PDRP |
| Longitudinal Change of Brain Network Activity | Pramipexole | Z score at 1 year (V5) | 4.09 | Standard Deviation 1.07 | Z-score in PDRP |
| Unified Parkinson's Disease Rating Score (UPDRS II, III) | Levodopa | UPDRS II at baseline (V1) | 7.3 | Standard Deviation 3.5 | units on a scale |
| Unified Parkinson's Disease Rating Score (UPDRS II, III) | Pramipexole | UPDRS II at baseline (V1) | 7.1 | Standard Deviation 2.9 | units on a scale |
| Unified Parkinson's Disease Rating Score (UPDRS II, III) | Levodopa | UPDRS II (V2) | 5.8 | Standard Deviation 3.5 | units on a scale |
| Unified Parkinson's Disease Rating Score (UPDRS II, III) | Pramipexole | UPDRS II (V2) | 4.9 | Standard Deviation 3.3 | units on a scale |
| Unified Parkinson's Disease Rating Score (UPDRS II, III) | Levodopa | UPDRS II at 1 year (V5) | 7.4 | Standard Deviation 3.5 | units on a scale |
| Unified Parkinson's Disease Rating Score (UPDRS II, III) | Pramipexole | UPDRS II at 1 year (V5) | 8.4 | Standard Deviation 3.0 | units on a scale |
| Unified Parkinson's Disease Rating Score (UPDRS II, III) | Levodopa | UPDRS III at baseline (V1) | 18.7 | Standard Deviation 7.7 | units on a scale |
| Unified Parkinson's Disease Rating Score (UPDRS II, III) | Pramipexole | UPDRS III at baseline (V1) | 23.1 | Standard Deviation 10.4 | units on a scale |
| Unified Parkinson's Disease Rating Score (UPDRS II, III) | Levodopa | UPDRS III (V2) | 12.7 | Standard Deviation 4.2 | units on a scale |
| Unified Parkinson's Disease Rating Score (UPDRS II, III) | Pramipexole | UPDRS III (V2) | 20.1 | Standard Deviation 8.9 | units on a scale |
| Unified Parkinson's Disease Rating Score (UPDRS II, III) | Levodopa | UPDRS III at 1 year (V5) | 19.5 | Standard Deviation 7.0 | units on a scale |
| Unified Parkinson's Disease Rating Score (UPDRS II, III) | Pramipexole | UPDRS III at 1 year (V5) | 24.3 | Standard Deviation 8.8 | units on a scale |
| Parkinson's Disease Questionnaire (PDQ39) | Levodopa | PDQ39 at baseline (V1) | 19.38 | Standard Deviation 10.94 | units on a scale |
| Parkinson's Disease Questionnaire (PDQ39) | Pramipexole | PDQ39 at baseline (V1) | 20.36 | Standard Deviation 16.49 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01470859/results